Published in Virology on May 01, 1992
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med (1994) 5.22
Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol (1995) 4.45
The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. J Exp Med (1994) 4.39
Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene. J Virol (1994) 4.14
Downregulation of cell-surface CD4 expression by simian immunodeficiency virus Nef prevents viral super infection. J Exp Med (1993) 3.29
Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell. J Virol (1995) 3.04
HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res (2005) 2.93
High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. J Virol (1996) 2.61
Human immunodeficiency virus type 1 Nef associates with a cellular serine kinase in T lymphocytes. Proc Natl Acad Sci U S A (1994) 2.48
A role for natural simian immunodeficiency virus and human immunodeficiency virus type 1 nef alleles in lymphocyte activation. J Virol (1997) 2.41
Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein. J Virol (1996) 2.40
Human immunodeficiency virus type 1 Nef-induced down-modulation of CD4 is due to rapid internalization and degradation of surface CD4. J Virol (1994) 2.17
Refined solution structure and backbone dynamics of HIV-1 Nef. Protein Sci (1997) 2.09
Expression of the human immunodeficiency virus type 1 (HIV-1) nef gene during HIV-1 production increases progeny particle infectivity independently of gp160 or viral entry. J Virol (1995) 2.08
Grossly defective nef gene sequences in a human immunodeficiency virus type 1-seropositive long-term nonprogressor. J Virol (1998) 1.99
Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection. J Virol (1995) 1.95
HIV-1 Nef increases T cell activation in a stimulus-dependent manner. Proc Natl Acad Sci U S A (1999) 1.92
Strict control of human immunodeficiency virus type 1 replication by a genetic switch: Tet for Tat. J Virol (2001) 1.89
Nef-mediated downregulation of CD4 enhances human immunodeficiency virus type 1 replication in primary T lymphocytes. J Virol (2002) 1.85
Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol (2001) 1.79
Upstream U3 sequences in simian immunodeficiency virus are selectively deleted in vivo in the absence of an intact nef gene. J Virol (1994) 1.77
Interactions between Nef and AIP1 proliferate multivesicular bodies and facilitate egress of HIV-1. Retrovirology (2006) 1.71
Human immunodeficiency virus type 1 Nef associates with a member of the p21-activated kinase family. J Virol (1996) 1.69
Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J Virol (1995) 1.56
Nef association with human immunodeficiency virus type 1 virions and cleavage by the viral protease. J Virol (1997) 1.55
Reduced cell surface expression of processed human immunodeficiency virus type 1 envelope glycoprotein in the presence of Nef. J Virol (1993) 1.48
In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein cytoplasmic tail. J Virol (2001) 1.45
Molecular biology of the human immunodeficiency virus accessory proteins. J Virol (1994) 1.44
Biological characterization of nef in long-term survivors of human immunodeficiency virus type 1 infection. J Virol (1995) 1.37
The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. Microbiol Rev (1995) 1.34
Human immunodeficiency virus type 1 nef quasispecies in pathological tissue. J Virol (1992) 1.33
Efficient class I major histocompatibility complex down-regulation by simian immunodeficiency virus Nef is associated with a strong selective advantage in infected rhesus macaques. J Virol (2001) 1.33
The proteolytic cleavage of human immunodeficiency virus type 1 Nef does not correlate with its ability to stimulate virion infectivity. J Virol (1998) 1.32
The human immunodeficiency virus type 1 nef gene can to a large extent replace simian immunodeficiency virus nef in vivo. J Virol (1999) 1.26
CD4 cell surface downregulation in HIV-1 Nef transgenic mice is a consequence of intracellular sequestration. EMBO J (1993) 1.17
A basic patch on alpha-adaptin is required for binding of human immunodeficiency virus type 1 Nef and cooperative assembly of a CD4-Nef-AP-2 complex. J Virol (2009) 1.17
Mechanistic independence of Nef and cyclophilin A enhancement of human immunodeficiency virus type 1 infectivity. Virology (1998) 1.17
Severe immunodeficiency associated with a human immunodeficiency virus 1 NEF/3'-long terminal repeat transgene. J Exp Med (1994) 1.13
The decreased replicative capacity of simian immunodeficiency virus SIVmac239Delta(nef) is manifest in cultures of immature dendritic cellsand T cells. J Virol (2000) 1.05
Recombinant human immunodeficiency virus type 1 genomes with tat unconstrained by overlapping reading frames reveal residues in Tat important for replication in tissue culture. J Virol (1996) 1.04
The nef gene products of both simian and human immunodeficiency viruses enhance virus infectivity and are functionally interchangeable. J Virol (1997) 1.03
Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias. Retrovirology (2006) 1.02
Human immunodeficiency virus type 1 Nef protein targets CD4 to the multivesicular body pathway. J Virol (2009) 1.00
Human immunodeficiency virus type 1 Nef protein down-regulates transcription factors NF-kappa B and AP-1 in human T cells in vitro after T-cell receptor stimulation. J Virol (1994) 1.00
Hairpin-induced tRNA-mediated (HITME) recombination in HIV-1. Nucleic Acids Res (2006) 0.97
Simian immunodeficiency virus containing mutations in N-terminal tyrosine residues and in the PxxP motif in Nef replicates efficiently in rhesus macaques. J Virol (2000) 0.96
Trans-inhibition of HIV-1 by a long hairpin RNA expressed within the viral genome. Retrovirology (2007) 0.95
Genetic and functional diversity of human immunodeficiency virus type 1 subtype B Nef primary isolates. J Virol (2001) 0.95
Human immunodeficiency virus type 1 infection of the brain. Clin Microbiol Rev (1993) 0.94
Primary human immunodeficiency virus type 1 nef alleles show major differences in pathogenicity in transgenic mice. J Virol (2007) 0.93
Viral modulation of T-cell receptor signaling. J Virol (2008) 0.93
The activity of Nef on HIV-1 infectivity. Front Microbiol (2014) 0.90
Inhibition of HIV-1 infection and replication by enhancing viral incorporation of innate anti-HIV-1 protein A3G: a non-pathogenic Nef mutant-based anti-HIV strategy. J Biol Chem (2009) 0.85
Vaccine effect using a live attenuated nef-deficient simian immunodeficiency virus of African green monkeys in the absence of detectable vaccine virus replication in vivo. Proc Natl Acad Sci U S A (1997) 0.85
Nef-mediated enhancement of cellular activation and human immunodeficiency virus type 1 replication in primary T cells is dependent on association with p21-activated kinase 2. Retrovirology (2011) 0.84
Exosomes are unlikely involved in intercellular Nef transfer. PLoS One (2015) 0.83
Simian immunodeficiency virus in which nef and U3 sequences do not overlap replicates efficiently in vitro and in vivo in rhesus macaques. J Virol (2001) 0.83
Understanding the MIND phenotype: macrophage/microglia inflammation in neurocognitive disorders related to human immunodeficiency virus infection. Clin Transl Med (2015) 0.81
Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis. Microbiol Mol Biol Rev (2000) 0.78
HIV's Nef interacts with β-catenin of the Wnt signaling pathway in HEK293 cells. PLoS One (2013) 0.76
Intracellular overexpression of HIV-1 Nef impairs differentiation and maturation of monocytic precursors towards dendritic cells. PLoS One (2012) 0.76
Detection of human immunodeficiency virus type 1 nucleocapsid protein p7 in vitro and in vivo. J Clin Microbiol (1999) 0.76
A consensus surface activation marker signature is partially dependent on human immunodeficiency virus type 1 Nef expression within productively infected macrophages. Retrovirology (2013) 0.76
New nucleotide sequence data on the EMBL File Server. Nucleic Acids Res (1992) 0.75
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol (1989) 8.32
Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci U S A (1988) 6.74
Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science (1997) 5.55
Antigenic diversity thresholds and the development of AIDS. Science (1991) 5.13
Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol (1992) 4.86
HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology (1992) 4.70
Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet (1986) 4.54
Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol (1992) 4.39
Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol (1994) 4.35
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis (1992) 4.21
Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet (1989) 4.19
Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol (1999) 4.04
Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J (1996) 3.92
Characterization of HIV-1 neutralization escape mutants. AIDS (1989) 3.88
Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. EMBO J (2003) 3.62
Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med (1990) 3.61
Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest (1988) 3.59
Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. AIDS (1988) 3.50
Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J Virol (1990) 3.35
HIV-1 V3 domain variation in brain and spleen of children with AIDS: tissue-specific evolution within host-determined quasispecies. Virology (1991) 3.33
Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. Br Med J (Clin Res Ed) (1986) 3.27
Changes in sexual behaviour and the fall in incidence of HIV infection among homosexual men. BMJ (1989) 3.16
Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med (1997) 3.08
Evolution of sequences encoding the principal neutralization epitope of human immunodeficiency virus 1 is host dependent, rapid, and continuous. Proc Natl Acad Sci U S A (1990) 2.78
Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus. Br Med J (Clin Res Ed) (1986) 2.75
Naturally occurring mutations within HIV-1 V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution. Virology (1991) 2.59
Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet (1990) 2.50
Reduced replication of human immunodeficiency virus type 1 mutants that use reverse transcription primers other than the natural tRNA(3Lys). J Virol (1995) 2.47
Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype. J Virol (1992) 2.41
Neutralization of HIV-1: a paradox of humoral proportions. FASEB J (1991) 2.41
Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS (2001) 2.41
Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects. Lancet (1988) 2.38
Risk factors and prevalence of HIV antibodies in homosexual men in the Netherlands. Am J Epidemiol (1987) 2.32
Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS (1998) 2.19
Universal cellular tropism? Nature (1992) 2.18
Antigenemia and antibody titers to core and envelope antigens in AIDS, AIDS-related complex, and subclinical human immunodeficiency virus infection. J Infect Dis (1987) 2.17
Human immunodeficiency virus type 1 subtypes defined by env show high frequency of recombinant gag genes. The UNAIDS Network for HIV Isolation and Characterization. J Virol (1996) 2.17
An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology (1994) 2.15
T cell telomere length in HIV-1 infection: no evidence for increased CD4+ T cell turnover. Science (1996) 2.12
Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS (1999) 2.09
Neurologic manifestations of human immunodeficiency virus infection in children. Pediatrics (1986) 2.09
Impact of HIV antibody testing on changes in sexual behavior among homosexual men in The Netherlands. Am J Public Health (1988) 2.07
N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem (2001) 2.07
Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. J Infect Dis (1988) 2.06
Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. J Infect Dis (1990) 2.06
Alternative view on AIDS. Lancet (1992) 2.06
Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period. J Virol (1995) 2.06
Risk factors for human herpesvirus 8 seropositivity and seroconversion in a cohort of homosexual men. Am J Epidemiol (2000) 2.05
The role of BK virus in acute respiratory tract disease and the presence of BKV DNA in tonsils. J Med Virol (1982) 2.04
Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia. Br Med J (Clin Res Ed) (1987) 2.02
Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses (1994) 1.99
Evolutionary relationships among parvoviruses: virus-host coevolution among autonomous primate parvoviruses and links between adeno-associated and avian parvoviruses. J Virol (2001) 1.98
AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS (1997) 1.97
A hairpin structure in the R region of the human immunodeficiency virus type 1 RNA genome is instrumental in polyadenylation site selection. J Virol (1999) 1.91
A conserved hairpin motif in the R-U5 region of the human immunodeficiency virus type 1 RNA genome is essential for replication. J Virol (1997) 1.91
Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene (2006) 1.88
HIV infection and STD in drug addicted prostitutes in Amsterdam: potential for heterosexual HIV transmission. Genitourin Med (1989) 1.88
Estimating relative fitness in viral competition experiments. J Virol (2000) 1.87
Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob Agents Chemother (1996) 1.85
Immunodominance and antigenic variation of the principal neutralization domain of HIV-1. Virology (1991) 1.85
The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology (1994) 1.85
Ongoing HIV dissemination during HAART. Nat Med (1999) 1.85
Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS (1993) 1.85
Improved silica-guanidiniumthiocyanate DNA isolation procedure based on selective binding of bovine alpha-casein to silica particles. J Clin Microbiol (1999) 1.81
Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol (2001) 1.79
Primary infections with HIV-1 of women and their offspring in Rwanda: findings of heterogeneity at seroconversion, coinfection, and recombinants of HIV-1 subtypes A and C. Virology (1997) 1.79
Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol (1997) 1.77
Increasing antigenic and genetic diversity of the V3 variable domain of the human immunodeficiency virus envelope protein in the course of the AIDS epidemic. Proc Natl Acad Sci U S A (1993) 1.77
OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol (2001) 1.75
Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. J Virol (1993) 1.70
Detecting dinosaur DNA. Science (1995) 1.69
Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2000) 1.68
Human antibody response to a strain-specific HIV-1 gp120 epitope associated with cell fusion inhibition. AIDS (1988) 1.68
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine (2010) 1.66
Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS (1999) 1.64
Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J Biol Chem (1999) 1.58
HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS (1999) 1.55
First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine (2008) 1.51
Expression of RNA and antigens of human immunodeficiency virus type-1 (HIV-1) in lymph nodes from HIV-1 infected individuals. Am J Pathol (1988) 1.48
HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS (1992) 1.47
Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection. AIDS (2000) 1.47
Binding of human immunodeficiency virus type-1 to follicular dendritic cells in vitro is complement dependent. J Immunol (1993) 1.45
In vivo selection of randomly mutated retroviral genomes. Nucleic Acids Res (1993) 1.44
The nucleotide sequence of a segment of Trypanosoma brucei mitochondrial maxi-circle DNA that contains the gene for apocytochrome b and some unusual unassigned reading frames. Nucleic Acids Res (1983) 1.44
Baboon endogenous virus evolution and ecology. Trends Microbiol (1996) 1.44
Qualitative and quantitative detection of HIV-1 RNA by nucleic acid sequence-based amplification. AIDS (1993) 1.44
Two distinct gamma-2 herpesviruses in African green monkeys: a second gamma-2 herpesvirus lineage among old world primates? J Virol (2000) 1.44
Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect Immun (2006) 1.43
Efficacy of the latest generation of antibody assays for (early) detection of HIV 1 and HIV 2 infection. Vox Sang (1989) 1.43